StockGlow

Guardant Health, Inc. (GH)

Blood tests that detect cancer mutations and guide treatment decisions.

$145.43-0.00%Healthcare
Compare GH with
StockGlow Score
89
Bullish
BearishBullish
1 year ago+251.1%

The outlook

Guardant Health is trading near $145.43 with strong analyst backing—the consensus sits at "Strong Buy" across 24 analysts. The stock sits well above both its 50- and 200-day moving averages and trades roughly 79% of the way through its 52-week range. The average analyst price target lies about 18% above the current price.

What’s behind the score

Analyst consensusStrong Buy — 1.3 avg of 24 analysts
Price trendAbove its 50- & 200-day averages
52-week range79% of the way from its 52-week low to high
Price targetAvg target +18% vs current price

Analyst price target

~12-month · 24 analysts
$171.08average target+17.6% vs now
Now $145.43
Low $90.00High $215.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$19.28B
52-wk high
$174.08
52-wk low
$40.35
50-day avg
$137.81
200-day avg
$105.58
Trailing P/E
—

Similar stocks

NTRANatera, Inc.$256.09-0.75%TXG10x Genomics, Inc.$46.76+1.82%NVCRNovoCure Limited$16.57-2.70%TWSTTwist Bioscience Corporation$86.92+0.44%VEEVVeeva Systems Inc.$201.20+3.46%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy